Get a reply from this employer — a resume and cover letter tailored to exactly what they’re hiring for.
Switch Therapeutics in South San Francisco is seeking a Senior/Principal Scientist to lead bioanalytical characterization of oligonucleotide therapeutics, integrating LC–MS/MS and LC–HRMS with PK/PD interpretation. This hands-on role guides method strategy and mentors junior scientists while collaborating across discovery and biology teams.
The position is full-time onsite with a competitive base salary and a compensation package including equity, a discretionary annual bonus, and comprehensive
We are seeking a Senior/Principal Scientist to lead the bioanalytical/analytical characterization of our oligonucleotide therapeutics. The role blends strong mass spectrometry capability with a broader bioanalytical and pharmacokinetic remit: you will develop and apply LC–MS/MS and LC–HRMS methods to quantify drug exposure and characterize stability and metabolism and connect those analytical results to pharmacokinetic and pharmacodynamic understanding.
You will work across the analytical workflow — from analyzing and extracting oligonucleotides out of plasma and complex tissues, through method development and data interpretation, to translating findings for project teams. It is a hands-on role that also carries technical influence: guiding method strategy and helping more junior scientists grow.
This role will require full-time onsite work at our research facilities in South San Francisco.
The pay range for this position at commencement of employment is expected to be between $150,000–$180,000 per year depending on experience. Base pay offered may vary depending on other factors, including job-related knowledge, skills, and experience. The total compensation package for this position may also include equity in the Company, a discretionary annual bonus, and a full range of healthcare and other benefits, including 401(k) eligibility and paid time off (including vacation, sick time, and parental leave). Details of participation in these benefit plans will be provided if a candidate receives an offer of employment.
If hired, the employee will be in an “at-will position” and the Company reserves the right to modify base salary (as well as any other discretionary payment or compensation program) at any time, including for reasons related to individual performance, Company or individual department/team performance, and market factors.
Switch Therapeutics is an emerging biotechnology company that is developing RNAi therapies stemming from transformative technologies invented at Caltech, City of Hope, and Harvard Medical School.
Switch’s conditionally activated siRNA (CASi) platform integrates RNA nanotechnology with RNA medicinal chemistry to create siRNA prodrugs that can activate or suppress their own drug activities based on the presence or absence of specific RNA markers in mammalian cells. This gives CASi-based drugs the ability to target specific cells responsible for disease while sparing non-target cells from drug activity.
Since its founding in Q3 2020, Switch has made significant progress in optimizing its technology for therapeutic applications and has generated highly compellingin vivovalidation data demonstrating distribution, potency, and duration of effect that support development for important disease indications.